A Study to Assess the Safety, Tolerability, and Pharmacodynamics of MK-8931/SCH 900931 in Patients With Alzheimer's Disease [Phase 1b; Protocol No. 010-00 (Also Known as P07820)].

Trial Profile

A Study to Assess the Safety, Tolerability, and Pharmacodynamics of MK-8931/SCH 900931 in Patients With Alzheimer's Disease [Phase 1b; Protocol No. 010-00 (Also Known as P07820)].

Completed
Phase of Trial: Phase I

Latest Information Update: 02 Nov 2016

At a glance

  • Drugs Verubecestat (Primary)
  • Indications Alzheimer's disease
  • Focus Pharmacodynamics
  • Most Recent Events

    • 02 Nov 2016 According to Merck & Co media release, reults were published online in Science Translational Medicine journal.
    • 02 Nov 2016 Results published in the Merck & Co Media Release.
    • 14 Jul 2013 Results presented at the Alzheimer's Association International Conference (AAIC), according to a media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top